123 / 1084
Oesophageal Cancer – CROSS Study
R
A
N
D
Primary endpoint: overall survival
N=363
T1N1M0
or
T2–3N0–1M0
Neoadjuvant R-CTX. 41,4 Gy:
Carbo AUC2 + Paclitaxel 50mg/m² weekly
RESECTION
© Universitätsmedizin Leipzig: University Cancer Center Leipzig (UCCL), Prof. Dr. F. Lordick
O
M
AC*
SCC**
RESECTION
Van Hagen et al.
N Engl J Med
2012; 366: 2074-2084
Shapiro J et al.,
Lancet Oncol
2015; 16: 1090–98
*AC: Adenocarcinoma
**SCC: Squamous cell cancer